Navigation Links
NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session
Date:3/28/2008

NEW YORK (March 27, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American College of Cardiology's 57th Annual Scientific Session in Chicago, March 29 to April 1. Among the most significant presentations are the following:

Drug-Eluting Stents Versus Bare-Metal Stents for Transplant Allograft Vasculopathy

Dr. Jeffrey Moses Director of the Center for Interventional Vascular Therapy and director of the Cardiac Catheterization Lab at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons

Heart transplant patients are more vulnerable to accelerated arteriosclerosis in their transplanted heart than the general population. In one of the largest studies of its kind, NewYork-Presbyterian/Columbia researchers found that drug-eluting stents were able to better keep arteries open and prevent narrowing than bare-metal stents. However, mortality rates for interventions were equal.


The Impact of Mandatory Angiographic Follow-up on the One-Year Clinical and Angiographic Results From Endeavor IV: A Randomized Comparison of the Endeavor Drug (ABT-578) Eluting Stent System vs. Taxus in De Novo Native Coronary Lesions

Dr. Martin B. Leon Associate director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is founder and chairman emeritus of the Cardiovascular Research Foundation in New York City.

This presentation will look at follow-up using angiograms and clinical outcomes on patients in the Endeavor IV study, which compares the Endeavor drug-eluting stent with the Taxus drug-eluting stent. The results indicate that clinical follow-up may be more meaningful in determining the true patient value of drug-eluting stents in preventing restenosis, the closing or narrowing of the previously-opened artery.


Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Baseline Renal Function on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Advanced Age on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-Eluting Stent Implantation: Pooled Analysis of the TAXUS IV and TAXUS V Trials

Dr. Gregg W. Stone Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is also chairman of the Cardiovascular Research Foundation in New York City.

Dr. Stone will present new findings from the HORIZONS AMI trial, which is evaluating the drug bivalirudin for heart attack patients undergoing angioplasty. Last year, investigators reported that the therapy reduces risk of death compared with the standard treatment. New findings look at several subsets, including older patients and patients with diabetes, finding bivalirudin also effective for these groups.

In addition, Dr. Stone will present findings from the TAXUS trials looking at the risk of restenosis and other negative outcomes in patients with diabetes with the Taxus drug-eluting stent.


'/>"/>

Contact: Bryan Dotson
brd9005@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
2. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
3. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
4. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. UC Irvine researchers present latest findings at emergency medicine forum
8. BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference
9. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
10. Health Fitness to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
11. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: